Search
CervoMed Inc
CRVOAdd to Watchlist
3.440USD
-0.320-8.51%
Close 05/15, 16:00（ET）Quotes delayed by 15 min
31.85MMarket Cap
LossP/E TTM
More Details of CervoMed Inc Company
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
CervoMed Inc Info
Ticker SymbolCRVO
Company nameCervoMed Inc
IPO dateNov 09, 2016
CEOAlam (John J)
Number of employees15
Security typeOrdinary Share
Fiscal year-endNov 09
Address20 Park Plaza, Suite 424
CityBOSTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02116
Phone16177444400
Websitehttps://cervomed.com/
Ticker SymbolCRVO
IPO dateNov 09, 2016
CEOAlam (John J)
Company Executives of CervoMed Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Joshua S. Boger, Ph.D.
Dr. Joshua S. Boger, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.06M
--
Mr. John J. Alam, M.D.
Mr. John J. Alam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
785.55K
+4.11%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Independent Director
Independent Director
16.44K
--
Ms. Kelly Blackburn
Ms. Kelly Blackburn
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
13.67K
--
Ms. Jane H. Hollingsworth, M.D.
Ms. Jane H. Hollingsworth, M.D.
Independent Director
Independent Director
899.00
--
Dr. Robert J. Cobuzzi, Jr.
Dr. Robert J. Cobuzzi, Jr.
Director
Director
--
--
Mr. William R. Elder
Mr. William R. Elder
Chief Financial Officer, General Counsel, Corporate Secretary
Chief Financial Officer, General Counsel, Corporate Secretary
--
--
Dr. Sylvie L. Gregoire, Pharm.D.
Dr. Sylvie L. Gregoire, Pharm.D.
Director
Director
--
--
Dr. Marwan Noel Sabbagh, M.D.
Dr. Marwan Noel Sabbagh, M.D.
Independent Director
Independent Director
--
--
Mr. Frank E. Zavrl
Mr. Frank E. Zavrl
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Joshua S. Boger, Ph.D.
Dr. Joshua S. Boger, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
1.06M
--
Mr. John J. Alam, M.D.
Mr. John J. Alam, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
785.55K
+4.11%
Mr. Jeffrey V. (Jeff) Poulton
Mr. Jeffrey V. (Jeff) Poulton
Independent Director
Independent Director
16.44K
--
Ms. Kelly Blackburn
Ms. Kelly Blackburn
Executive Vice President - Clinical Development
Executive Vice President - Clinical Development
13.67K
--
Ms. Jane H. Hollingsworth, M.D.
Ms. Jane H. Hollingsworth, M.D.
Independent Director
Independent Director
899.00
--
Dr. Robert J. Cobuzzi, Jr.
Dr. Robert J. Cobuzzi, Jr.
Director
Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, May 14
Updated: Thu, May 14
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Boger (Joshua S)
11.42%
Gregoire (Sylvie L.)
8.48%
Alam (John J)
8.48%
Morgan Stanley & Co. LLC
5.08%
Zavrl (Frank E.)
3.81%
Other
62.72%
Shareholders
Shareholders
Proportion
Boger (Joshua S)
11.42%
Gregoire (Sylvie L.)
8.48%
Alam (John J)
8.48%
Morgan Stanley & Co. LLC
5.08%
Zavrl (Frank E.)
3.81%
Other
62.72%
Shareholder Types
Shareholders
Proportion
Individual Investor
32.84%
Investment Advisor
6.66%
Research Firm
5.21%
Hedge Fund
1.32%
Investment Advisor/Hedge Fund
1.31%
Venture Capital
0.11%
Other
52.55%
Institutional Shareholding
Updated: Wed, Apr 1
Updated: Wed, Apr 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2026Q1
130
1.35M
14.61%
-2.93M
2025Q4
123
2.18M
45.61%
--
2025Q3
124
2.18M
46.47%
-3.07K
2025Q2
112
2.18M
47.13%
-111.10K
2025Q1
106
2.29M
39.48%
-1.15M
2024Q4
98
1.50M
41.86%
-2.03M
2024Q3
82
3.52M
43.30%
+50.30K
2024Q2
68
3.46M
36.20%
+585.47K
2024Q1
43
2.52M
7.33%
+2.06M
2023Q4
40
327.50K
7.25%
-36.20K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Boger (Joshua S)
1.06M
11.42%
--
--
Apr 24, 2025
Gregoire (Sylvie L.)
753.29K
8.14%
+22.50K
+3.08%
Nov 17, 2025
Alam (John J)
753.29K
8.14%
+22.50K
+3.08%
Nov 17, 2025
Morgan Stanley & Co. LLC
470.63K
5.08%
+60.48K
+14.75%
Dec 31, 2025
Zavrl (Frank E.)
353.01K
3.81%
--
--
Apr 24, 2025
Geode Capital Management, L.L.C.
65.88K
0.71%
+1.41K
+2.19%
Dec 31, 2025
Millennium Management LLC
60.27K
0.65%
-11.24K
-15.72%
Dec 31, 2025
Citadel Advisors LLC
49.25K
0.53%
+18.74K
+61.42%
Dec 31, 2025
BlackRock Institutional Trust Company, N.A.
48.07K
0.52%
+302.00
+0.63%
Dec 31, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 Growth ETF
0%
Global X Russell 2000 ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Health Innovation Active ETF
0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0%
iShares Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Health Innovation Active ETF
Proportion0%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0%
iShares Russell 2000 ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Apr 18, 2022
Merger
50→1
Apr 18, 2022
Merger
50→1
Date
Ex-dividend Date
Type
Ratio
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Aug 16, 2023
Merger
1.5→1
Apr 18, 2022
Merger
50→1
Apr 18, 2022
Merger
50→1
Apr 18, 2022
Merger
50→1
Apr 18, 2022
Merger
50→1
